Mutual antagonism of T cells causing psoriasis and atopic eczema.

The scalp is a well-known predilection site for psoriasis. Epidemiological data on the various manifestations of scalp psoriasis as well as on its therapeutic management are sparse. The understanding of the natural course of scalp psoriasis is relevant for its therapeutic management. In over 25% of patients, scalp psoriasis is the first signal of the psoriatic condition. Nevertheless, few of the therapies currently used for the treatment of scalp psoriasis have been evaluated for efficacy in the setting of well-designed, well-controlled clinical studies. The lack of comparative data impedes the interpretation of the results from studies of scalp psoriasis. Long-term studies of the efficacy and safety of scalp treatments are lacking. Moreover, clinical studies generally do not incorporate quality of life impact or mechanisms to enhance adherence thus hindering the optimal management of the patient over the long-term. Consequently, this report will evaluate the available data and the associated factors to be considered in the development of a treatment paradigm for the long-term management of the scalp psoriasis patient. Biopharmaceuticals and Biosimilars in Psoriasis: What the Dermatologist needs to Know. (2012) B.E. Strober, K. Armour, R. Romiti, C. Smith, P.W. Tebbey, A. Menter and C. Leonardi, on behalf of the International Psoriasis Council. Journal of the American Academy of Dermatology. 66 (2)317-322.